HTGF at al. provide seed funding for Oncgnostics

An additional €100,000 was provided by STIFT, a vehicle of the German region of Thüringen that holds €25-30m in funds.

The investment will back the clinical development of Oncgnostics's diagnostic tests, which may be launched in the future in conjunction with HPV test suppliers.

Company
Oncgnostics was founded as a spin-off of the university hospital Jena in February 2012. The company focuses on the development of accurate molecular diagnostic tests for use in cancer screening, therapy decision and follow-up care.

Founding members include Professor Matthias Dürst, leader of the gynaecological molecular biology lab, Alfred Hansel, Martina Schmitz and economist Kerstin Brox.

People
Dr Bernd Goergen, senior investment manager at HTGF, led the investment with Dr Sven Günther, managing director of STIFT.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• DACH
• Healthcare
• High-Tech Gründerfonds
• Germany